echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > A multi-center clinical study led by Zhongzhong, Fuzhong and Zhe Er confirmed that blood circulating tumor DNA can be used to predict the risk of recurrence of colorectal cancer after surgery

    A multi-center clinical study led by Zhongzhong, Fuzhong and Zhe Er confirmed that blood circulating tumor DNA can be used to predict the risk of recurrence of colorectal cancer after surgery

    • Last Update: 2021-06-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On May 17, 2021, a multi-center research team led by Zhongzhong, Fudan and Zhejiang No.
    2 published an online publication titled “Postoperative circulating tumor DNA can be used as II/ in the well-known international oncology journal “Hematology and Oncology”.
    The latest research results of "Stage III Colorectal Cancer Recurrence Risk Markers" (
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.